725 terminated. 725 Phase 1, 260 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 725 | Terminated 725 |
| Phase 2 | 260 | Terminated 260 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-08-24 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Antigen-specific T cells CART/CTL and DCvac - B-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-08-24 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-08-24 |
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-08-24 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma CD38-SADA:177Lu-DOTA Complex - Non-hodgkin Lymphoma | Phase 1 | Terminated | Y-mAbs Therapeutics | 1 | 2025-04-21 | 2026-03-12 |
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) AUR104 - Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 9 | 2024-12-12 | 2026-04-17 |
| A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma ONO-7018 - Non Hodgkin Lymphoma | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 2 | 2024-11-27 | 2026-07-29 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ATA3219 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Atara Biotherapeutics | 1 | 2024-09-06 | 2026-03-11 |
| A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas ASP2802, MA-20 - B-cell Lymphoma | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 1 | 2024-09-06 | 2025-10-28 |
| Study of Tazemetostat in Lymphoid Malignancies Tazemetostat - T-cell Lymphoma | Phase 1 | Terminated | University of Alabama at Birmingham | 6 | 2024-09-05 | 2026-04-17 |
| Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Descartes-15 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 4 | 2024-06-19 | 2025-11-24 |
| A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers PF-08046044/SGN-35C - Hodgkin Disease, Lymphoma, T-Cell, Peripheral | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 58 | 2024-05-28 | 2026-07-06 |
| Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma LUCAR-G39P cells product - Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | The First Affiliated Hospital with Nanjing Medical University | 11 | 2024-04-11 | 2025-12-01 |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma IPH6501 - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Innate Pharma | 23 | 2024-03-04 | 2026-04-14 |
| A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers PF-08046045 - Lymphoma, T-Cell, Cutaneous, Hodgkin Disease | Phase 1 | Terminated | Seagen, a wholly owned subsidiary of Pfizer | 22 | 2024-02-29 | 2026-07-06 |
| A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma Alnuctamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Celgene | 4 | 2024-02-27 | 2026-04-21 |
| C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma C752 - Lymphoma, B-Cell, CAR-T | Phase 1 | Terminated | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 2 | 2023-12-24 | 2025-02-18 |
Showing 20 of 725. Sign in to see all of them.
Multiple Myeloma (211) · Lymphoma, Non-Hodgkin (178) · Lymphoma (175) · Leukemia, Lymphocytic, Chronic, B-Cell (153) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (132) · Lymphoma, Large B-Cell, Diffuse (117) · Recurrence (106) · Lymphoma, Follicular (96) · Leukemia (85) · Leukemia, Myeloid, Acute (83) · Lymphoma, Mantle-Cell (82) · Hodgkin Disease (65) · Burkitt Lymphoma (63) · Lymphoma, B-Cell, Marginal Zone (56) · Myelodysplastic Syndromes (56)
Immune System Diseases (722) · Immunoproliferative Disorders (721) · Hemic and Lymphatic Diseases (719) · Neoplasms by Histologic Type (717) · Neoplasms (665) · Lymphatic Diseases (563) · Hematologic Diseases (459) · Pathological Conditions, Signs and Symptoms (278) · Pathologic Processes (275) · Disease Attributes (263) · Lymphoma (254) · Leukemia, Lymphoid (246) · Paraproteinemias (242) · Cardiovascular Diseases (238)
Rituximab (74) · Dexamethasone (71) · Cyclophosphamide (50) · Lenalidomide (41) · Bortezomib (36) · fludarabine (33) · Calcium Dobesilate (31) · venetoclax (23) · Gemcitabine (21) · Melphalan (19) · Vincristine (19) · pembrolizumab (18) · pomalidomide (18) · Cytarabine (17) · Filgrastim (17)
National Cancer Institute (NCI) (44) · M.D. Anderson Cancer Center (33) · Celgene (18) · Novartis Pharmaceuticals (16) · Gilead Sciences (13) · Masonic Cancer Center, University of Minnesota (10) · Merck Sharp & Dohme LLC (10) · Fred Hutchinson Cancer Center (9) · Incyte Corporation (9) · Northwestern University (9) · Pfizer (9) · Amgen (8) · Hoffmann-La Roche (8) · Washington University School of Medicine (8) · GlaxoSmithKline (7)
United States (597) · Spain (81) · France (70) · Italy (59) · Australia (51) · Canada (43) · Germany (43) · China (42) · United Kingdom (38) · Japan (30) · South Korea (28) · Belgium (19) · Israel (18) · Netherlands (18) · Poland (13)
Ajay Gopal (4)
PMID 34515338, PMID 34398557, PMID 31215818, PMID 31527168, PMID 32823563, PMID 35226739, PMID 35622074, PMID 36597128, PMID 39097413, PMID 18297527, PMID 18645136, PMID 19029442, PMID 19139736, PMID 19238148, PMID 20460644, PMID 20563869, PMID 21289631, PMID 22080439, PMID 22080968, PMID 22239668, PMID 22250189, PMID 22448921, PMID 23092873, PMID 23233571, PMID 23256542, PMID 23393050, PMID 23400739, PMID 24241210, PMID 24276047, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 25441108, PMID 25655379, PMID 26139427, PMID 26384354, PMID 26472751, PMID 26567113, PMID 26687959, PMID 27118540, PMID 28140719, PMID 28261656, PMID 28461396, PMID 28903943, PMID 29141948, PMID 29296805, PMID 29322091, PMID 29432154, PMID 29477379
2018 (13), 2023 (11), 2015 (10), 2016 (9), 2017 (8), 2019 (8), 2014 (7), P30CA015704 (6), U01CA076576 (6), P30CA015083 (5), P30CA043703 (4), U01CA097452 (4), 2008 (3), P01CA044991 (3), P30CA006973 (3)